> News > A FIT Tech Growth Loan for Volumina Medical

A FIT Tech Growth Loan for Volumina Medical

Volumina Medical is developing regenerative and degradable implants for minimally invasive reconstructive breast surgery. The CHF 500’000 loan from the Foundation for Technological Innovation (FIT) will enable Volumina to conduct a clinical study in Europe. 

Volumina Medical – Degradable implants supporting the human body to repair. Spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL), Volumina Medical is developing highly innovative biomaterials for regenerative medicine. Their solutions address high unmet needs for the markets of reconstructive and plastic surgery. Volumina’s first product is Adipearl, a leading innovative biomaterial being developed to support the repair of soft tissues, initially targeting breast reconstruction after cancer surgery. Each year, around 2 million women are diagnosed with breast cancer worldwide, 500’000 of whom are in Europe. These patients increasingly resort to reconstructive surgeries to regain their natural and healthy physical appearance. Unfortunately, today, the available techniques are either too burdensome, induce long-term foreign body reactions, require repeated surgeries or do not bring durable results. In addition, a high number of patients are not eligible for one of these techniques and remain untreated. To address this significant unmet medical need, Volumina Medical has been working for several years on the development of a platform of novel injectable biomaterials to support soft tissue repair. The lead product from this work is Adipearl which has gone through extensive pre-clinical studies and is now being tested in patients. First therapeutic target is breast reconstruction following cancer surgery. Thanks to the FIT loan, Volumina Medical will conduct a first in human clinical study in Europe.

Read the full news on fondation-fit.ch

Company related to the news